Source: Eur Respir J, 50 (4) 1701848; 10.1183/13993003.01848-2017
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Tom M.A. Wilkinson. Are inhaled corticosteroids increasing the “load” for some patients with COPD?. Eur Respir J, 50 (4) 1701848; 10.1183/13993003.01848-2017

Member's Comments

No comment yet.

Related content which might interest you: Is GLCCI1 associated with response to inhaled corticosteroids in asthma patients? Source: Annual Congress 2012 - Gene-environment treatment and asthma Year: 2012 Are COPD patients with pneumonia who are taking inhaled corticosteroids at higher risk of dying? Source: Eur Respir J 2011; 37: 1-3 Year: 2011 The effects of nebulised bronchodilators and corticosteroids treatment compared with inhaled drug therapy for moderate COPD patients Source: Eur Respir J 2004; 24: Suppl. 48, 290s Year: 2004 What to use INSTEAD of inhaled corticosteroids in COPD? Source: Eur Respir J 2014; 44: 1391-1393 Year: 2014 Clinically important deteriorations in COPD as a measure of response to dual and mono bronchodilator therapy with and without inhaled corticosteroids Source: International Congress 2015 – New data on established treatments for COPD Year: 2015 Reduced risk for asthma exacerbations in pediatric patients receiving salmeterol plus inhaled corticosteroids (ICS) vs. ICS alone Source: Eur Respir J 2004; 24: Suppl. 48, 308s Year: 2004 Is there a problem with inhaled corticosteroid use in COPD? Source: Virtual Congress 2020 – Airway diseases Year: 2020 Inhaled corticosteroids and the risk of a first exacerbation in COPD patients Source: Eur Respir J 2004; 23: 692-697 Year: 2004 The effect of combined β2-agonist and anticholinergic inhaled therapy in patients with COPD Source: Eur Respir J 2004; 24: Suppl. 48, 341s Year: 2004 Children with mild asthma: do they benefit from inhaled corticosteroids? Source: Eur Respir J 2002; 20: 1470-1475 Year: 2002 Treatment with inhaled corticosteroids (ICS) in patients with COPD: possible way of optimisation Source: Annual Congress 2009 - Drug effects in COPD Year: 2009 The pharmacogenomics of inhaled corticosteroids and lung function decline in COPD Source: Eur Respir J, 54 (6) 1900521; 10.1183/13993003.00521-2019 Year: 2019 ERS guideline on withdrawal of inhaled corticosteroids in COPD Source: ERS webinar 2021: ERS guideline on withdrawal of inhaled corticosteroids in COPD Year: 2021 Comparing pneumonia incidence in COPD patients treated with or without inhaled corticosteroid Source: Virtual Congress 2021 – Inhaled treatments for COPD: real-world data Year: 2021 Bronchodilator reversibility and short-term inhaled corticosteroid response in Japanese patients with COPD Source: Eur Respir J 2004; 24: Suppl. 48, 341s Year: 2004 Control of persistent asthma patients on inhaled corticosteroids in a real-life setting Source: Annual Congress 2010 - New insights in the epidemiology of asthma Year: 2010 Lung function changes over time following withdrawal of inhaled corticosteroids in patients with severe COPD Source: Eur Respir J 2016; 47: 651-654 Year: 2016 Quality of life of patients with asthma exacerbations treated with high doses of inhaled corticosteroids Source: Eur Respir J 2002; 20: Suppl. 38, 114s Year: 2002 Predictors of inhaled corticosteroid therapy in COPD alone compared to COPD with concomitant asthma managed in primary care Source: International Congress 2019 – Multimorbidity in airway diseases and appropriate inhaled corticosteroid use in COPD Year: 2019 Osteoporosis risk assessment in elderly male patients with COPD who use inhaled corticosteroids Source: Annual Congress 2006 - COPD therapy Year: 2006